The problem of osteoporosis in epileptic patients taking antiepileptic drugs

Expert Opinion on Drug Safety

Volumn 13, Issue 7, 2014, Pages 935-946

  Miziak, Barbara ^a   Błaszczyk, Barbara ^b   Chrościńska Krawczyk, Magdalena ^a   Danilkiewicz, Grzegorz ^a   Jagiełło Wójtowicz, Ewa ^a   Czuczwar, Stanisław J ^a,c  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^b High School of Economics and Law   (Poland)

^c INSTITUTE OF AGRICULTURAL MEDICINE   (Poland)

Author keywords

Antiepileptic drugs; Calcium supplementation; Fractures; Osteoporosis; Vitamin D supplementation

Indexed keywords

ANTICONVULSIVE AGENT; CALCIUM; CARBAMAZEPINE; CLONAZEPAM; ENZYME; ETHOSUXIMIDE; ETIRACETAM; GABAPENTIN; HARKOSERIDE; LAMOTRIGINE; LIVER ENZYME; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PREGABALIN; PRIMIDONE; TIAGABINE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN; VITAMIN D;

BONE DENSITY; BONE DISEASE; BONE METABOLISM; EPILEPSY; HUMAN; NONHUMAN; OSTEOLYSIS; OSTEOPOROSIS; POSTMENOPAUSE OSTEOPOROSIS; REVIEW; RISK FACTOR; TREATMENT DURATION; TREATMENT INDICATION; VITAMIN SUPPLEMENTATION; CHEMICALLY INDUCED; DRUG EFFECTS;

ANTICONVULSANTS; BONE DENSITY; EPILEPSY; HUMANS; OSTEOPOROSIS;

EID: 84902690039     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2014.919255     Document Type: Review

References (123)

1. Tarride JE, Hopkins RB, Leslie WD, et al. The burden of illness of osteoporosis in Canada. Osteoporos Int 2012;23:2591-600
2. Ratti C, Vulcano E, Canton G, et al. Factors affecting bone strength other than osteoporosis. Aging Clin Exp Res 2013;25(Suppl 1):9-11
3. Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 2006;17:1726-33
4. Murray CJ, Lopez AP. Global and regional descriptive epidemiology of disability. Incidence, prevalence, health expectancies and years lived with disability. In: Murray CJL, Lopez AD, editors. The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries and risk factors in 1990 and projected to 2020. Cambridge University Press, Cambridge; 1996. p. 201-46
5. Jacobs-Kosmin D, Hobar C, Chanmugam S. Metabolic and bone disease: osteoporosis. Available from: http://emedicine.medscape.com/article/330598-print [Accessed 5 October 2009]
6. Jetté N, Lix LM, Metge CJ, et al. Association of antiepileptic drugs with nontraumatic fractures: a population-based analysis. Arch Neurol 2011;68:107-12
7. Lyngstad-Brechan MA, Taubøll E, Nakken KO, et al. Reduced bone mass and increased bone turnover in postmenopausal women with epilepsy using antiepileptic drug monotherapy. Scand J Clin Lab Invest 2008;68:759-66
8. Pack AM, Morrell MJ. Adverse effects of antiepileptic drugs on bone structure: epidemiology, mechanisms and therapeutic implications. CNS Drugs 2001;15:633-42
9. von Borstel Smith M, Crofoot K, Rodriguez-Proteau R, Filtz TM. Effects of phenytoin and carbamazepine on calcium transport in Caco-2 cells. Toxicol In Vitro 2007;21:855-62
10. Bauer S, Hofbauer LC, Rauner M, et al. Early detection of bone metabolism changes under different antiepileptic drugs (ED-BoM-AED)-A prospective multicenter study. Epilepsy Res 2013;106:417-22
11. Pack A. Bone health in people with epilepsy: is it impaired and what are the risk factors? Seizure 2008;17:181-6
12. Beerhorst K, Tan IY, De Krom M, et al. Antiepileptic drugs and high prevalence of low bone mineral density in a group of inpatients with chronic epilepsy. Acta Neurol Scand 2013;128:273-80
13. Sheth RD, Gidal BE, Hermann BP. Pathological fractures in epilepsy. Epilepsy Behav 2006;9:601-5
14. Souverein PC, Webb DJ, Petri H, et al. Incidence of fractures among epilepsy patients: a population-based retrospective cohort study in the general practice research database. Epilepsia 2005;46:304-10
15. Mattson RH, Gidal BE. Fractures, epilepsy, and antiepileptic drugs. Epilepsy Behav 2004;5(Suppl 2):S36-40
16. Ensrud KE, Walczak TS, Blackwell T, et al. Antiepileptic drug use increases rates of bone loss in older women: a prospective study. Neurology 2004;62:2051-7
17. Feldkamp J, Becker A, Witte OW, et al. Long-term anticonvulsant therapy leads to low bone mineral density-evidence for direct drug effects of phenytoin and carbamazepine on human osteoblast-like cells. Exp Clin Endocrinol Diabetes 2000;108:37-43
18. Fitzpatrick LA. Pathophysiology of bone loss in patients receiving anticonvulsant therapy. Epilepsy Behav 2004;5(Suppl 2):S3-15
19. Beniczky SA, Viken J, Jensen LT, Andersen NB. Bone mineral density in adult patients treated with various antiepileptic drugs. Seizure 2012;21:471-2
20. Verrotti A, Coppola G, Parisi P, et al. Bone and calcium metabolism and antiepileptic drugs. Clin Neurol Neurosurg 2010;112:1-10
21. Tsiropoulos I, Andersen M, Nymark T, et al. Exposure to antiepileptic drugs and the risk of hip fracture: a case-control study. Epilepsia 2008;49:2092-9
22. Espinosa PS, Perez DL, Abner E, Ryan M. Association of antiepileptic drugs, vitamin D, and calcium supplementation with bone fracture occurrence in epilepsy patients. Clin Neurol Neurosurg 2011;113:548-51
23. Beerhorst K, van der Kruijs SJ, Verschuure P, et al. Bone disease during chronic antiepileptic drug therapy: general versus specific risk factors. J Neurol Sci 2013;331:19-25
24. Nicholas JM, Ridsdale L, Richardson MP, et al. Fracture risk with use of liver enzyme inducing antiepileptic drugs in people with active epilepsy: cohort study using the general practice research database. Seizure 2013;22:37-42
25. Khanna S, Pillai KK, Vohora D. Insights into liaison between antiepileptic drugs and bone. Drug Discov Today 2009;14:428-35
26. Pack AM, Morrell MJ, McMahon DJ, Shane E. Normal vitamin D and low free estradiol levels in women on enzyme-inducing antiepileptic drugs. Epilepsy Behav 2011;21:453-8
27. Kim SH, Lee JW, Choi KG, et al. A 6-month longitudinal study of bone mineral density with antiepileptic drug monotherapy. Epilepsy Behav 2007;10:291-5
28. Lee RH, Lyles KW, Colón-Emeric C. A review of the effect of anticonvulsant medications on bone mineral density and fracture risk. Am J Geriatr Pharmacother 2010;8:34-46
29. Svalheim S, Røste LS, Nakken KO, Taubøll E. Bone health in adults with epilepsy. Acta Neurol Scand Suppl 2011;191:89-95
30. Pack AM, Morrell MJ, Randall A, et al. Bone health in young women with epilepsy after one year of antiepileptic drug monotherapy. Neurology 2008;70:1586-93
31. Gniatkowska-Nowakowska A. Fractures in epilepsy children. Seizure 2010;19:324-5
32. Koo DL, Hwang KJ, Han SW, et al. Effects of oxcarbazepine on bone mineral density and biochemical markers of bone metabolism in patients with epilepsy. Epilepsy Res 2013, doi:10.1016/j.eplepsyres.2013.09.009
33. Välimäki MJ, Tiihonen M, Laitinen K, et al. Bone mineral density measured by dual-energy X-ray absorptiometry and novel markers of bone formation and resorption in patients on antiepileptic drugs. J Bone Miner Res 1994;9:631-7
34. Pack AM, Morrell MJ, Marcus R, et al. Bone mass and turnover in women with epilepsy on antiepileptic drug monotherapy. Ann Neurol 2005;57:252-7
35. Hegedüs L, Hansen JM, Lühdorf K, et al. Increased frequency of goitre in epileptic patients on long-term phenytoin or carbamazepine treatment. Clin Endocrinol (Oxf) 1985;23:423-9
36. Nakade O, Baylink DJ, Lau KH. Phenytoin at micromolar concentrations is an osteogenic agent for human-mandible-derived bone cells in vitro. J Dent Res 1995;74:331-7
37. Onodera K, Takahashi A, Mayanagi H, et al. Phenytoin-induced bone loss and its prevention with alfacalcidol or calcitriol in growing rats. Calcif Tissue Int 2001;69:109-16
38. Nissen-Meyer LS, Svalheim S, Taubøll E, et al. Levetiracetam, phenytoin, and valproate act differently on rat bone mass, structure, and metabolism. Epilepsia 2007;48:1850-60
39. Takahashi A, Onodera K, Shinoda H, Mayanagi H. Phenytoin and its metabolite, 5-(4-hydroxyphenyl)-5-phenylhydantoin, show bone resorption in cultured neonatal mouse calvaria. Jpn J Pharmacol 2000;82:82-4
40. Schmitt BP, Nordlund DJ, Rodgers LA. Prevalence of hypocalcemia and elevated serum alkaline phosphatase in patients receiving chronic anticonvulsant therapy. J Fam Pract 1984;18:873-7
41. Weisman Y, Fattal A, Eisenberg Z, et al. Decreased serum 24, 25-dihydroxy vitamin D concentrations in children receiving chronic anticonvulsant therapy. Br Med J 1979;2:521-3
42. Hosseinpour F, Ellfolk M, Norlin M, Wikvall K. Phenobarbital suppresses vitamin D3 25-hydroxylase expression: a potential new mechanism for drug-induced osteomalacia. Biochem Biophys Res Commun 2007;357:603-7
43. Foss MC, Meneghelli UG, Tabosa Veŕissimo JM. The effect of the anticonvulsants phenobarbital and diphenylhydantoin on intestinal absorption of calcium. Acta Physiol Lat Am 1979;29:223-8
44. Tjellesen L, Gotfredsen A, Borg J, Christiansen C. Relationship between local and total body bone mineral in epileptic patients and normal subjects. Clin Physiol 1983;3:359-64
45. Tjellesen L, Nilas L, Christiansen C. Does carbamazepine cause disturbances in calcium metabolism in epileptic patients? Acta Neurol Scand 1983;68:13-19
46. Verrotti A, Greco R, Latini G, et al. Increased bone turnover in prepubertal, pubertal, and postpubertal patients receiving carbamazepine. Epilepsia 2002;43:1488-92
47. Sheth RD, Wesolowski CA, Jacob JC, et al. Effect of carbamazepine and valproate on bone mineral density. J Pediatr 1995;127:256-62
48. Cansu A, Yesilkaya E, Serdaroglu A, et al. Evaluation of bone turnover in epileptic children using oxcarbazepine. Pediatr Neurol 2008;39:266-71
49. Verrotti A, Greco R, Morgese G, Chiarelli F. Increased bone turnover in epileptic patients treated with carbamazepine. Ann Neurol 2000;47:385-8
50. Ecevit C, Aydogan A, Kavakli T, Altin€oz S. Effect of carbamazepine and valproate on bone mineral density. Pediatr Neurol 2004;31:279-82
51. Kumandas S, Koklu E, Gümüs H, et al. Effect of carbamezapine and valproic acid on bone mineral density, IGF-I and IGFBP-3. J Pediatr Endocrinol Metab 2006;19:529-34
52. Voudris KA, Attilakos A, Katsarou E, et al. Early alteration in bone metabolism in epileptic children receiving carbamazepine monotherapy owing to the induction of hepatic drug-metabolizing enzymes. J Child Neurol 2005;20:513-16
53. Nicolaidou P, Georgouli H, Kotsalis H, et al. Effects of anticonvulsant therapy on vitamin D status in children: prospective monitoring study. J Child Neurol 2006;21(3):205-9
54. Tjellesen L, Gotfredsen A, Christiansen C. Effect of vitamin D2 and D3 on bone-mineral content in carbamazepine-treated epileptic patients. Acta Neurol Scand 1983;68:424-8
55. Larkin JG, McKee PJ, Forrest G, et al. Lack of enzyme induction with oxcarbazepine (600 mg daily) in healthy subjects. Br J Clin Pharmacol 1991;31:65-71
56. Patsalos PN, Zakrzewska JM, Elyas AA. Dose dependent enzyme induction by oxcarbazepine? Eur J Clin Pharmacol 1990;39:187-8
57. Mintzer S, Boppana P, Toguri J, DeSantis A. Vitamin D levels and bone turnover in epilepsy patients taking carbamazepine or oxcarbazepine. Epilepsia 2006;47:510-15
58. Triantafyllou N, Lambrinoudaki I, Armeni E, et al. Effect of long-term valproate monotherapy on bone mineral density in adults with epilepsy. J Neurol Sci 2010;290:131-4
59. Humphrey EL, Morris GE, Fuller HR. Valproate reduces collagen and osteonectin in cultured bone cells. Epilepsy Res 2013;106:446-50
60. Cho GW, Kang BY, Kim KS, Kim SH. Effects of valproic acid on the expression of trophic factors in human bone marrow mesenchymal stromal cells. Neurosci Lett 2012;526:100-5
61. Boluk A, Guzelipek M, Savli H, et al. The effect of valproate on bone mineral density in adult epileptic patients. Pharmacol Res 2004;50:93-7
62. Fuller HR, Man NT, Lam le T, et al. Valproate and bone loss: iTRAQ proteomics show that valproate reduces collagens and osteonectin in SMA cells. J Proteome Res 2010;9:4228-33
63. Sheth RD, Hermann BP. Bone mineral density with lamotrigine monotherapy for epilepsy. Pediatr Neurol 2007;37:250-4
64. Zhang J, Wang KX, Wei Y, et al. [Effect of topiramate and carbamazepine on bone metabolism in children with epilepsy]. [Article in Chinese]. Zhongguo Dang Dai Er Ke Za Zhi 2010;12:96-8
65. Heo K, Rhee Y, Lee HW, et al. The effect of topiramate monotherapy on bone mineral density and markers of bone and mineral metabolism in premenopausal women with epilepsy. Epilepsia 2011;52:1884-9
66. Stephen LJ, McLellan AR, Harrison JH, et al. Bone density and antiepileptic drugs: a case-controlled study. Seizure 1999;8:339-42
67. Koo DL, Joo EY, Kim D, Hong SB. Effects of levetiracetam as a monotherapy on bone mineral density and biochemical markers of bone metabolism in patients with epilepsy. Epilepsy Res 2013;104:134-9
68. Ali II, Herial NA, Horrigan T, et al. Measurement of bone mineral dendity in patients on levetiracetam monotherapy. Am Epilepsy Soc Abstr 2006;2:150
69. Fekete S, Simko J, Gradosova I, et al. The effect of levetiracetam on rat bone mass, structure and metabolism. Epilepsy Res 2013;107:56-60
70. Guo CY, Ronen GM, Atkinson SA. Long-term valproate and lamotrigine treatment may be a marker for reduced growth and bone mass in children with epilepsy. Epilepsia 2001;42:1141-7
71. Winnacker JL, Yeager H, Saunders JA, et al. Rickets in children receiving anticonvulsant drugs. Biochemical and hormonal markers. Am J Dis Child 1977;131:286-90
72. Gough H, Goggin T, Bissessar A, et al. A comparative study of the relative influence of different anticonvulsant drugs, UV exposure and diet on vitamin D and calcium metabolism in out-patients with epilepsy. Q J Med 1986;59:569-77
73. Farhat G, Yamout B, Mikati MA, et al. Effect of antiepileptic drugs on bone density in ambulatory patients. Neurology 2002;58:1348-53
74. Persson HB, Alberts KA, Farahmand BY, Tomson T. Risk of extremity fractures in adult outpatients with epilepsy. Epilepsia 2002;43:768-72
75. Tekgul H, Dizdarer G, Demir N, et al. Antiepileptic drug-induced osteopenia in ambulatory epileptic children receiving a standard vitamin D3 supplement. J Pediatr Endocrinol Metab 2005;18:585-8
76. Souverein PC, Webb DJ, Weil JG, et al. Use of antiepileptic drugs and risk of fractures: case-control study among patients with epilepsy. Neurology 2006;66:1318-24
77. Cansu A, Serdaroglu A, Camurdan O, et al. The evaluation of thyroid functions, thyroid antibodies, and thyroid volumes in children with epilepsy during short-term administration of oxcarbazepine and valproate. Epilepsia 2006;47:1855-9
78. Vestergaard P, Rejnmark L, Mosekilde L. Fracture risk associated with use of antiepileptic drugs. Epilepsia 2004;45:1330-7
79. Isojärvi JI, Turkka J, Pakarinen AJ, et al. Thyroid function in men taking carbamazepine, oxcarbazepine, or valproate for epilepsy. Epilepsia 2001;42:930-4
80. Seibel MJ. Molecular markers of bone turnover: biochemical, technical and analytical aspects. Osteoporos Int 2000;11(Suppl 6):S18-29
81. Hahn TJ, Scharp CR, Richardson CA, et al. Interaction of diphenylhydantoin (phenytoin) and phenobarbital with hormonal mediation of fetal rat bone resorption in vitro. J Clin Invest 1978;62:406-14
82. Peck WA, Dowling I. Failure of 1, 25 dihydroxycholecalciferol (1, 25-(OH) 2-D3) to modify cyclic AMP levels in parathyroid hormone-treated and untreated bone cells. Endocr Res Commun 1976;3:157-66
83. Meier C, Kraenzlin ME. Antiepileptics and bone health. Ther Adv Musculoskelet Dis 2011;3:235-43
84. Petty SJ, O'Brien TJ, Wark JD. Anti-epileptic medication and bone health. Osteoporos Int 2007;18:129-42
85. Mintzer S. Metabolic consequences of antiepileptic drugs. Curr Opin Neurol 2010;23:164-9
86. Pothiwala P, Evans EM, Chapman-Novakofski KM. Ethnic variation in risk for osteoporosis among women: a review of biological and behavioral factors. J Womens Health (Larchmt) 2006;15:709-19
87. Barrett-Connor E, Siris ES, Wehren LE, et al. Osteoporosis and fracture risk in women of different ethnic groups. J Bone Miner Res 2005;20:185-94
88. Nissen-Meyer LS, Svalheim S, Taubøll E, et al. How can antiepileptic drugs affect bone mass, structure and metabolism? Lessons from animal studies. Seizure 2008;17:187-91
89. Hoikka V, Savolainen K, Alhava EM, et al. Osteomalacia in institutionalized epileptic patients on long-term anticonvulsant therapy. Acta Neurol Scand 1981;64:122-31
90. Kanbur NO, Derman O, Sen TA, Kinik E. Osteocalcin. A biochemical marker of bone turnover during puberty. Int J Adolesc Med Health 2002;14:235-44
91. Glastre C, Braillon P, David L, et al. Measurement of bone mineral content of the lumbar spine by dual energy X-ray absorptiometry in normal children: correlations with growth parameters. J Clin Endocrinol Metab 1990;70:1330-3
92. del Rio L, Carrascosa A, Pons F, et al. Bone mineral density of the lumbar spine in white Mediterranean Spanish children and adolescents: changes related to age, sex, and puberty. Pediatr Res 1994;35:362-6
93. Saggese G, Baroncelli GI, Bertelloni S. Puberty and bone development. Best Pract Res Clin Endocrinol Metab 2002;16:53-64
94. Erbayat Altay E, Serdaroglu A, Tümer L, et al. Evaluation of bone mineral metabolism in children receiving carbamazepine and valproic acid. J Pediatr Endocrinol Metab 2000;13:933-9
95. Kafali G, Erselcan T, Tanzer F. Effect of antiepileptic drugs on bone mineral density in children between ages 6 and 12 years. Clin Pediatr (Phila) 1999;38:93-8
96. Aronson E, Stevenson SB. Bone health in children with cerebral palsy and epilepsy. J Pediatr Health Care 2012;26:193-9
97. Henderson RC, Lark RK, Gurka MJ, et al. Bone density and metabolism in children and adolescents with moderate to severe cerebral palsy. Pediatrics 2002;110:e5
98. Brunner R, Doderlein L. Pathological fractures in patients with cerebral palsy. J Pediatr Orthop B 1996;5:232-8
99. Houlihan CM, Stevenson RD. Bone density in cerebral palsy. Phys Med Rehabil Clin N Am 2009;20:493-508
100. Bischof F, Basu D, Pettifor JM. Pathological long-bone fractures in residents with cerebral palsy in a long-term care facility in South Africa. Dev Med Child Neurol 2002;44:119-22
101. Thommessen M, Kase BF, Riis G, Heiberg A. The impact of feeding problems on growth and energy intake in children with cerebral palsy. Eur J Clin Nutr 1991;45:479-87
102. Sullivan PB, Lambert B, Rose M, et al. Prevalence and severity of feeding and nutritional problems in children with neurological impairment: Oxford Feeding Study. Dev Med Child Neurol 2000;42:674-80
103. Coppola G, Fortunato D, Auricchio G, et al. Bone mineral density in children, adolescents, and young adults with epilepsy. Epilepsia 2009;50:2140-6
104. Babayigit A, Dirik E, Bober E, Cakmakci H. Adverse effects of antiepileptic drugs on bone mineral density. Pediatr Neurol 2006;35:177-81
105. Richens A, Rowe DJ. Disturbance of calcium metabolism by anticonvulsant drugs. Br Med J 1970;4:73-6
106. Andress DL, Ozuna J, Tirschwell D, et al. Antiepileptic drug-induced bone loss in young male patients who have seizures. Arch Neurol 2002;59:781-6
107. Ensrud KE, Walczak TS, Blackwell TL, et al. Antiepileptic drug use and rates of hip bone loss in older men: a prospective study. Neurology 2008;71:723-30
108. Valmadrid C, Voorhees C, Litt B, Schneyer CR. Practice patterns of neurologists regarding bone and mineral effects of antiepileptic drug therapy. Arch Neurol 2001;58:1369-74
109. Fong CY, Mallick AA, Burren CP, Patel JS. Evaluation and management of bone health in children with epilepsy on long-term antiepileptic drugs: United Kingdom survey of paediatric neurologists. Eur J Paediatr Neurol 2011;15:417-23
110. Lazzari AA, Dussault PM, Thakore-James M, et al. Prevention of bone loss and vertebral fractures in patients with chronic epilepsy-antiepileptic drug and osteoporosis prevention trial. Epilepsia 2013;54:1997-2004
111. Delmas PD. Treatment of postmenopausal osteoporosis. Lancet 2002;359:2018-26
112. Harden CL. The current state of postmenopausal hormone therapy: update for neurologists and epileptologists. Epilepsy Curr 2007;7:119-22
113. Delaney MF. Strategies for the prevention and treatment of osteoporosis during early postmenopause. Am J Obstet Gynecol 2006;194(Suppl 2):S12-23
114. Drezner MK. Treatment of anticonvulsant drug-induced bone disease. Epilepsy Behav 2004;5(Suppl 2):S41-7
115. Collins N, Mahe J, Cole M, et al. A prospective study to evaluate the dose of vitamin D required to correct low 25-hydroxyvitamin D levels, calcium, and alkaline phosphatase in patients at risk of developing antiepileptic drug-induced osteomalacia. Q J Med 1991;78:113-22
116. Ali FE, Al-Bustan MA, Al-Busairi WA, Al-Mulla FA. Loss of seizure control due to anticonvulsant-induced hypocalcemia. Ann Pharmacother 2004;38:1002-5
117. Glauser T, Ben-Menachem E, Bourgeois B, et al. Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia 2013;54:551-63
118. Lason W, Dudra-Jastrzebska M, Rejdak K, Czuczwar SJ. Basic mechanisms of antiepileptic drugs and their pharmacokinetic/pharmacodynamic interactions: an update. Pharmacol Rep 2011;63:271-92
119. Florek-Luszczki M, Wlaz A, Luszczki JJ. Interactions of levetiracetam with carbamazepine, phenytoin, topiramate and vigabatrin in the mouse 6Hz psychomotor seizure model-A type II isobolographic analysis. Eur J Pharmacol 2014;723:410-18
120. Luszczki JJ, Filip R, Florek-Luszczki M. Interactions of pregabalin with gabapentin, levetiracetam, tiagabine and vigabatrin in the mouse maximal electroshock-induced seizure model: a type II isobolographic analysis. Epilepsy Res 2012;98:148-56
121. Jette N, Lix LM, Metge CJ, et al. Association of antiepileptic drugs with nontraumatic fractures. Arch Neurol 2011;68:107-12
122. Meier C, Kraenzlin ME. Antiepileptics and bone health. Ther Adv Musculoskelet Dis 2011;3:235-43
123. Beerhorst K, Schovenaars FM, Tan IY, Aldenkamp AP. Epilepsy: fractures and the role of cumulative antiepileptic drug load. Acta Neurol Scand 2012;125:54-9